Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5279197
Max Phase: Preclinical
Molecular Formula: C32H31Br6N3O10
Molecular Weight: 1097.04
Associated Items:
ID: ALA5279197
Max Phase: Preclinical
Molecular Formula: C32H31Br6N3O10
Molecular Weight: 1097.04
Associated Items:
Canonical SMILES: COC1=C(Br)[C@@H](O)[C@]2(C=C1Br)CC(C(=O)NCCCOc1c(Br)cc(C(O)CNC(=O)C3=NO[C@@]4(C=C(Br)C(OC)=C(Br)[C@H]4O)C3)cc1Br)=CO2
Standard InChI: InChI=1S/C32H31Br6N3O10/c1-47-25-18(35)9-31(27(43)22(25)37)8-15(13-50-31)29(45)39-4-3-5-49-24-16(33)6-14(7-17(24)34)21(42)12-40-30(46)20-11-32(51-41-20)10-19(36)26(48-2)23(38)28(32)44/h6-7,9-10,13,21,27-28,42-44H,3-5,8,11-12H2,1-2H3,(H,39,45)(H,40,46)/t21?,27-,28-,31-,32+/m1/s1
Standard InChI Key: CZYTVSJBVRHQJA-FIIPYWKRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1097.04 | Molecular Weight (Monoisotopic): 1090.7110 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Mishra SK, Tripathi G, Kishore N, Singh RK, Singh A, Tiwari VK.. (2017) Drug development against tuberculosis: Impact of alkaloids., 137 [PMID:28628823] [10.1016/j.ejmech.2017.06.005] |
Source(1):